Skip to main content
Premium Trial:

Request an Annual Quote

Salvatore Salamone, Jim Manzi

Premium
US Genomics has named Salvatore Salamone to its board of directors.
 
Salamone is chairman and CEO of Saladax Biomedical. He formerly was vice president of R&D at Roche Diagnostics and was senior vice president of R&D at Orasure Technologies.
 

 
Thermo Fisher Scientific has named director Jim Manzi as non-executive chairman of its board.
 
Manzi previously served as the company’s chairman of Thermo Electron from December 2003 until November 2006, when the company merged with Fisher Scientific. He succeeds Paul Meister, who resigned last month.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.